Loading...
•
Mar 31, 2024
Bio-Techne Q3 2024 Earnings Report
Bio-Techne's Q3 2024 performance reflected solid top-line growth and strong commercial execution amid challenging market conditions.
Key Takeaways
Bio-Techne reported a 3% increase in revenue to $303.4 million, with organic revenue growth of 2%. GAAP EPS was $0.31, while adjusted EPS reached $0.48. The Diagnostics & Genomics segment demonstrated strong growth, with 10% organic segment growth. Cash flow from operations increased by 31% to $223.5 million.
Organic revenue increased by 2% (3% reported) to $303.4 million.
GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago, with adjusted EPS of $0.48 compared to $0.53 one year ago.
Diagnostics & Genomics segment led to 10% organic segment growth (16% reported).
Cash flow generated from operations increased to $223.5 million, a 31% increase from the prior year.
Revenue by Segment
Forward Guidance
No forward guidance was provided in the earnings report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...